Martin Bonde leaves consultancy firm for CEO position in Swiss company
Experienced biotech leader Martin Bonde leaves Danish Novo Seeds' consultancy firm Biorigin to become CEO of a Swiss cancer company, where Novo Seeds is also a major investor. "I just had to accept," he says.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY IDA LØJMAND
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.